Vanda Pharmaceuticals (VNDA) Operating Margin (2010 - 2026)

Vanda Pharmaceuticals has disclosed Operating Margin across 17 years of filings, most recently posting 97.11% for Q1 2026.

• Operating Margin for Q1 2026 came in at 97.11%, down 1512.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 73.64% (down 3765.0% YoY), and the FY2025 annual result was 69.95%, down 4950.0% from the prior year.
• Operating Margin came in at 97.11% for Q1 2026 at Vanda Pharmaceuticals, down from 70.53% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 10.28% in Q4 2022 to a low of 97.11% in Q1 2026.
• The 5-year median for Operating Margin is 19.33% (2024), against an average of 28.57%.
• Across the five-year window, Operating Margin surged 1595 bps in 2023 and tumbled 6253 bps in 2025, its largest moves.
• Vanda Pharmaceuticals' Operating Margin stood at 10.28% in 2022, then plunged by 252 bps to 15.67% in 2023, then decreased by 23 bps to 19.33% in 2024, then sank by 265 bps to 70.53% in 2025, then tumbled by 38 bps to 97.11% in 2026.
• The last three Operating Margin figures came in at 97.11% (Q1 2026), 70.53% (Q4 2025), and 55.61% (Q3 2025), per Business Quant data.